Papers associated with central nervous system (and grin1)

Limit to papers also referencing gene:
Show all central nervous system papers

???pagination.result.count???

???pagination.result.page??? 1 2 ???pagination.result.next???

Sort Newest To Oldest

Sort Oldest To Newest

	Advancements in the use of xenopus oocytes for modelling neurological disease for novel drug discovery., O'Connor EC., Expert Opin Drug Discov. February 1, 2024; 19 (2): 173-187.
	Recurrent seizure-related GRIN1 variant: Molecular mechanism and targeted therapy., Xu Y., Ann Clin Transl Neurol. July 1, 2021; 8 (7): 1480-1494.
	Positive allosteric modulators that target NMDA receptors rectify loss-of-function GRIN variants associated with neurological and neuropsychiatric disorders., Tang W., Neuropharmacology. October 15, 2020; 177 108247.
	Postsynaptic and Presynaptic NMDARs Have Distinct Roles in Visual Circuit Development., Kesner P., Cell Rep. July 28, 2020; 32 (4): 107955.
	De novo GRIN variants in NMDA receptor M2 channel pore-forming loop are associated with neurological diseases., Li J., Hum Mutat. December 1, 2019; 40 (12): 2393-2413.
	An NMDAR positive and negative allosteric modulator series share a binding site and are interconverted by methyl groups., Perszyk R., Elife. May 24, 2018; 7
	All naturally occurring autoantibodies against the NMDA receptor subunit NR1 have pathogenic potential irrespective of epitope and immunoglobulin class., Castillo-Gómez E., Mol Psychiatry. December 1, 2017; 22 (12): 1776-1784.
	Lin28 proteins are required for germ layer specification in Xenopus., Faas L., Development. March 1, 2013; 140 (5): 976-86.
	A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons., Kostakis E., J Neurochem. November 1, 2011; 119 (3): 486-96.
	The DREAM protein negatively regulates the NMDA receptor through interaction with the NR1 subunit., Zhang Y, Zhang Y., J Neurosci. June 2, 2010; 30 (22): 7575-86.
	Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-aspartate receptor antagonists., Hansen KB., J Pharmacol Exp Ther. June 1, 2010; 333 (3): 650-62.
	Regulation of radial glial motility by visual experience., Tremblay M., J Neurosci. November 11, 2009; 29 (45): 14066-76.
	Neuroprotection by tosyl-polyamine derivatives through the inhibition of ionotropic glutamate receptors., Masuko T., J Pharmacol Exp Ther. November 1, 2009; 331 (2): 522-30.
	Molecular and functional characterization of Xenopus laevis N-methyl-d-aspartate receptors., Schmidt C., Mol Cell Neurosci. October 1, 2009; 42 (2): 116-27.
	Cloning and Phylogenetic Analysis of NMDA Receptor Subunits NR1, NR2A and NR2B in Xenopus laevis Tadpoles., Ewald RC., Front Mol Neurosci. September 11, 2009; 2 4.
	The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors., Yuan H., J Biol Chem. May 8, 2009; 284 (19): 12862-73.
	Effects of NR1 splicing on NR1/NR3B-type excitatory glycine receptors., Cavara NA., BMC Neurosci. April 6, 2009; 10 32.
	Pharmacological characterization of recombinant NR1/NR2A NMDA receptors with truncated and deleted carboxy termini expressed in Xenopus laevis oocytes., Puddifoot CA., Br J Pharmacol. February 1, 2009; 156 (3): 509-18.
	Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-D-aspartate receptor., Han X., J Neurochem. December 1, 2008; 107 (6): 1566-77.
	Differential effect of high pressure on NMDA receptor currents in Xenopus laevis oocytes., Mor A., Diving Hyperb Med. December 1, 2008; 38 (4): 194-6.
	Tissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function., Samson AL., J Neurochem. November 1, 2008; 107 (4): 1091-101.
	The NR1 M3 domain mediates allosteric coupling in the N-methyl-D-aspartate receptor., Blanke ML., Mol Pharmacol. August 1, 2008; 74 (2): 454-65.
	Constitutive activation of the N-methyl-D-aspartate receptor via cleft-spanning disulfide bonds., Blanke ML., J Biol Chem. August 1, 2008; 283 (31): 21519-29.
	Modulation of glycine potency in rat recombinant NMDA receptors containing chimeric NR2A/2D subunits expressed in Xenopus laevis oocytes., Chen PE., J Physiol. January 1, 2008; 586 (1): 227-45.
	Molecular and functional studies of tilapia (Oreochromis mossambicus) NMDA receptor NR1 subunits., Tzeng DW., Comp Biochem Physiol B Biochem Mol Biol. March 1, 2007; 146 (3): 402-11.
	Equilibrium constants for (R)-[(S)-1-(4-bromo-phenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl]-phosphonic acid (NVP-AAM077) acting at recombinant NR1/NR2A and NR1/NR2B N-methyl-D-aspartate receptors: Implications for studies of synaptic transmission., Frizelle PA., Mol Pharmacol. September 1, 2006; 70 (3): 1022-32.
	RNA interference of Xenopus NMDAR NR1 in vitro and in vivo., Miskevich F., J Neurosci Methods. April 15, 2006; 152 (1-2): 65-73.
	Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity., Woods AS., J Proteome Res. April 1, 2006; 5 (4): 1017-23.
	Tweaking agonist efficacy at N-methyl-D-aspartate receptors by site-directed mutagenesis., Hansen KB., Mol Pharmacol. December 1, 2005; 68 (6): 1510-23.
	Synthesis, binding affinity at glutamic acid receptors, neuroprotective effects, and molecular modeling investigation of novel dihydroisoxazole amino acids., Conti P., J Med Chem. October 6, 2005; 48 (20): 6315-25.
	Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels., Chen HS., J Pharmacol Exp Ther. September 1, 2005; 314 (3): 961-71.
	The NR3B subunit does not alter the anesthetic sensitivities of recombinant N-methyl-D-aspartate receptors., Yamakura T., Anesth Analg. June 1, 2005; 100 (6): 1687-1692.
	Glutamate transporter type 3 attenuates the activation of N-methyl-D-aspartate receptors co-expressed in Xenopus oocytes., Zuo Z., J Exp Biol. June 1, 2005; 208 (Pt 11): 2063-70.
	Structural features of the glutamate binding site in recombinant NR1/NR2A N-methyl-D-aspartate receptors determined by site-directed mutagenesis and molecular modeling., Chen PE., Mol Pharmacol. May 1, 2005; 67 (5): 1470-84.
	Molecular interactions of the type 1 human immunodeficiency virus transregulatory protein Tat with N-methyl-d-aspartate receptor subunits., Chandra T., Neuroscience. January 1, 2005; 134 (1): 145-53.
	Monoamines directly inhibit N-methyl-D-aspartate receptors expressed in Xenopus oocytes in a voltage-dependent manner., Masuko T., Neurosci Lett. November 16, 2004; 371 (1): 30-3.
	Differential modulation of NR1-NR2A and NR1-NR2B subtypes of NMDA receptor by PDZ domain-containing proteins., Iwamoto T., J Neurochem. April 1, 2004; 89 (1): 100-8.
	Functional analysis of Caenorhabditis elegans glutamate receptor subunits by domain transplantation., Strutz-Seebohm N., J Biol Chem. November 7, 2003; 278 (45): 44691-701.
	Dynorphin A inhibits NMDA receptors through a pH-dependent mechanism., Kanemitsu Y., Mol Cell Neurosci. November 1, 2003; 24 (3): 525-37.
	Structural model of the N-methyl-D-aspartate receptor glycine site probed by site-directed chemical coupling., Foucaud B., J Biol Chem. June 27, 2003; 278 (26): 24011-7.
	Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids., Malayev A., Br J Pharmacol. February 1, 2002; 135 (4): 901-9.
	The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801., Rammes G., Neuropharmacology. May 1, 2001; 40 (6): 749-60.
	Effects of volatile solvents on recombinant N-methyl-D-aspartate receptors expressed in Xenopus oocytes., Cruz SL., Br J Pharmacol. December 1, 2000; 131 (7): 1303-8.
	Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors., Low CM., Proc Natl Acad Sci U S A. September 26, 2000; 97 (20): 11062-7.
	NMDA receptor subunit gene expression in the rat brain: a quantitative analysis of endogenous mRNA levels of NR1Com, NR2A, NR2B, NR2C, NR2D and NR3A., Goebel DJ., Brain Res Mol Brain Res. June 8, 1999; 69 (2): 164-70.
	Investigation by ion channel domain transplantation of rat glutamate receptor subunits, orphan receptors and a putative NMDA receptor subunit., Villmann C., Eur J Neurosci. May 1, 1999; 11 (5): 1765-78.
	Differentiation of glycine antagonist sites of N-methyl-D-aspartate receptor subtypes. Preferential interaction of CGP 61594 with NR1/2B receptors., Honer M., J Biol Chem. May 1, 1998; 273 (18): 11158-63.
	Adjacent asparagines in the NR2-subunit of the NMDA receptor channel control the voltage-dependent block by extracellular Mg2+., Wollmuth LP., J Physiol. January 1, 1998; 506 ( Pt 1) 13-32.
	An active-site histidine of NR1/2C mediates voltage-independent inhibition by zinc., Gray AT., Brain Res Mol Brain Res. December 1, 1997; 52 (1): 157-61.
	Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids., Park-Chung M., Mol Pharmacol. December 1, 1997; 52 (6): 1113-23.

???pagination.result.page??? 1 2 ???pagination.result.next???